← Leaderboards
Gregory M Cole
Va Greater Los Angeles Healthcare System
$11,212,815
Attributed
$13,765,758
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $938.5K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$13,765,758 · 8
VA$0 · 3
By mechanism
R01$10,146,944 · 5
P50$2,618,814 · 2
RC1$1,000,000 · 1
I01$0 · 3
Top collaborators
- Konrad Talbot7 shared
- Sally Ann Frautschy3 shared
Most similar at Va Greater Los Angeles Healthcare System
Same institution · by research overlap
- Sally Ann Frautschy$9,944,052
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposSynapsesS DiseasePathologyBrainResponseInflammationBaseProteinsS Disease ModelApolipoprotein EPharmaceutical PreparationsAnimal ModelPathogenesisChronicCognitive DeficitsLaboratory MouseMediatingNerve DegenerationTau ProteinsProtein IsoformsTransgenic MiceCognitionAmyloid Proteins
Grant awards (56)
CTBI: Tauopathy in mice and human: Surrogate Plasma Biomarkers for Brain Trauma-Initiated Neurodegenerative Disease$0
I01 · FY2023 · VA · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$684,076
R01 · FY2022 · AG
CTBI: Tauopathy in mice and human: Surrogate Plasma Biomarkers for Brain Trauma-Initiated Neurodegenerative Disease$0
I01 · FY2022 · VA · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$684,515
R01 · FY2021 · AG
CTBI: Tauopathy in mice and human: Surrogate Plasma Biomarkers for Brain Trauma-Initiated Neurodegenerative Disease$0
I01 · FY2021 · VA · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$690,558
R01 · FY2020 · AG
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$193,430
R01 · FY2020 · AG
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$54,500
R01 · FY2020 · AG
CTBI: Tauopathy in mice and human: Surrogate Plasma Biomarkers for Brain Trauma-Initiated Neurodegenerative Disease$0
I01 · FY2020 · VA · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$746,208
R01 · FY2019 · AG
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$682,885
R01 · FY2018 · AG
How to modulate innate immune function to prevent age-related neurodegeneration$0
I01 · FY2018 · VA · contact PI
How to modulate innate immune function to prevent age-related neurodegeneration$0
I01 · FY2017 · VA · contact PI
How to modulate innate immune function to prevent age-related neurodegeneration$0
I01 · FY2016 · VA · contact PI
Preclinical Pharmacogenomics and Synaptic Biomarkers for Alzheimer's Disease$369,715
R01 · FY2015 · AT · contact PI
How to modulate innate immune function to prevent age-related neurodegeneration$0
I01 · FY2015 · VA · contact PI
Preclinical Pharmacogenomics and Synaptic Biomarkers for Alzheimer's Disease$369,716
R01 · FY2014 · AT · contact PI
Preclinical Pharmacogenomics and Synaptic Biomarkers for Alzheimer's Disease$369,716
R01 · FY2013 · AT · contact PI
Mechanisms for NSAID Alzheimer Prevention$0
I01 · FY2013 · VA · contact PI
Preclinical Pharmacogenomics and Synaptic Biomarkers for Alzheimer's Disease$381,150
R01 · FY2012 · AT · contact PI
Mechanisms for NSAID Alzheimer Prevention$0
I01 · FY2012 · VA · contact PI
Preclinical Pharmacogenomics and Synaptic Biomarkers for Alzheimer's Disease$385,000
R01 · FY2011 · AT · contact PI
Mechanisms for NSAID Alzheimer Prevention$0
I01 · FY2011 · VA · contact PI
Diet and Exercise (DE) Program for Alzheimer Prevention$500,000
RC1 · FY2010 · AG · contact PI
NSAID Inhibition of Alzheimer Pathology: Role of DHA$243,335
R01 · FY2010 · AG · contact PI
Diet and Exercise (DE) Program for Alzheimer Prevention$500,000
RC1 · FY2009 · AG · contact PI
NSAID Inhibition of Alzheimer Pathology: Role of DHA$245,793
R01 · FY2009 · AG · contact PI
Mechanisms for NSAID Alzheimer Prevention$0
I01 · FY2009 · VA · contact PI
Can Omega 3 fatty acids Slow Alzheimer Pathogenesis?$265,272
R01 · FY2008 · AT · contact PI
NSAID Inhibition of Alzheimer Pathology: Role of DHA$245,793
R01 · FY2008 · AG · contact PI
OXIDATIVE DAMAGE TO SYNAPTIC COMPARTMENTS IN AD$231,413
P50 · FY2008 · AG · contact PI
Can Omega 3 fatty acids Slow Alzheimer Pathogenesis?$270,686
R01 · FY2007 · AT · contact PI
NSAID Inhibition of Alzheimer Pathology: Role of DHA$250,809
R01 · FY2007 · AG · contact PI
OXIDATIVE DAMAGE TO SYNAPTIC COMPARTMENTS IN AD$237,058
P50 · FY2007 · AG · contact PI
Can Omega 3 fatty acids Slow Alzheimer Pathogensis?$270,686
R01 · FY2006 · AT · contact PI
NSAID Inhibition of Alzheimer Pathology: Role of DHA$258,300
R01 · FY2006 · AG · contact PI
OXIDATIVE DAMAGE TO SYNAPTIC COMPARTMENTS IN AD$203,144
P50 · FY2006 · AG · contact PI
Can Omega 3 fatty acids Slow Alzheimer Pathogenesis?$265,646
R01 · FY2005 · AT
AMEYLOID VACCINE, AMYLOID REMOVAL MECHANISMS AND SYNAPTI$252,000
R01 · FY2005 · NS
OXIDATIVE DAMAGE TO SYNAPTIC COMPARTMENTS IN AD$197,665
P50 · FY2005 · AG
AMEYLOID VACCINE, AMYLOID REMOVAL MECHANISMS AND SYNAPTI$252,000
R01 · FY2004 · NS
OXIDATIVE DAMAGE TO SYNAPTIC COMPARTMENTS IN AD$191,305
P50 · FY2004 · AG
AMEYLOID VACCINE, AMYLOID REMOVAL MECHANISMS AND SYNAPTI$252,000
R01 · FY2003 · NS
NSAID Inhibition Microglial Activation and AD Pathology$239,400
R01 · FY2003 · AG
AMEYLOID VACCINE, AMYLOID REMOVAL MECHANISMS AND SYNAPTI$252,000
R01 · FY2002 · NS
NSAID Inhibition Microglial Activation and AD Pathology$239,400
R01 · FY2002 · AG
LIPOPROTEIN DEPENDENT A-BETA DEPOSITION IN BRAIN$228,564
P50 · FY2002 · AG
AMYLOID VACCINE &AMYLOID REMOVAL MECHANISMS$277,000
R01 · FY2001 · NS
NSAID Inhibition Microglial Activation and AD Pathology$263,150
R01 · FY2001 · AG
LIPOPROTEIN DEPENDENT A-BETA DEPOSITION IN BRAIN$228,564
P50 · FY2001 · AG
LIPOPROTEIN DEPENDENT A-BETA DEPOSITION IN BRAIN$228,404
P50 · FY2001 · AG
LIPOPROTEIN DEPENDENT A-BETA DEPOSITION IN BRAIN$228,404
P50 · FY2000 · AG
LIPOPROTEIN DEPENDENT A-BETA DEPOSITION IN BRAIN$228,404
P50 · FY2000 · AG
LIPOPROTEIN DEPENDENT A-BETA DEPOSITION IN BRAIN$228,404
P50 · FY2000 · AG
MICROGLIAL/LIPOPROTEIN INTERACTIONS WITH BETA-AMYLOID$192,205
R01 · FY2000 · AG
LIPOPROTEIN DEPENDENT A-BETA DEPOSITION IN BRAIN$187,485
P50 · FY2000 · AG